Prot #PCYC-1127-CA: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom’s Macroglobulinemia

Project: Research project

Project Details

StatusFinished
Effective start/end date10/14/1412/31/20

Funding

  • PPD Development (Prot #PCYC-1127-CA)
  • Pharmacyclics, Inc. (Prot #PCYC-1127-CA)